AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company that became publicly traded through its merger with Priveterra Acquisition Corp, a blank-check company that completed its IPO in 2021. Sponsored by Priveterra Holdings LLC, the SPAC targeted the healthcare and life sciences sector, ultimately combining with AEON to advance the company's pipeline of botulinum toxin-based therapeutics. AEON filed an 8-K with the SEC on February 24, 2025, under accession number 0001837607-25-000013, reflecting ongoing public-company reporting obligations following the completed de-SPAC transaction. The company operates within the biopharmaceuticals industry, focusing on therapeutic applications of its proprietary formulations. Sign up at SpacDesk for full filing history, deal timelines, and sponsor analytics on AEON and hundreds of other SPAC transactions.